Avelox in Complicated Skin and Skin Structure Infections (ARTOS)

Bayer

Status: Completed

Conditions: Skin Diseases, Bacterial

Treatments: Drug: Moxifloxacin (Avelox, BAY12-8039)

Study type: Observational

Funder types: Industry

Identifiers

NCT00997997

12754 (AX0502GR) (Other Identifier)

12519 (AX0502SI) (Other Identifier)

12237 (AX0502AT) (Other Identifier)

12236 (AX0502DE) (Other Identifier)

13165 (AX0502PH) (Other Identifier)

12646 (AX0502PK) (Other Identifier)

13924 (AX0502SA) (Other Identifier)

12865 (AX0502KR) (Other Identifier)

13045 (AX0502ID) (Other Identifier)

12237

12645 (AX0502BG) (Other Identifier)

13206 (AX0502EG) (Other Identifier)

12866 (AX0502TW) (Other Identifier)

Details and patient eligibility

About

This international, prospective, non-interventional, non-controlled observational study obtains data on efficacy, safety and tolerability of Avelox treatment under daily-life treatment conditions. Specifically investigated are the improvement of clinical symptoms and the duration until infection improvement and cure.Any patient with a diagnosis of complicated skin and skin structure infection (cSSSI) treated with Avelox can be documented. The observation period for each subject covers the treatment period with Avelox. For each patient, the physician documents data at an initial visit and one or two follow-up visit(s) in line with routine practice.

Enrollment: 6,127 patients

Sex: All

Ages: 10+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Any patient with a diagnosis of complicated skin and skin structure infection (cSSSI) and for whom the decision was made by the attending physician to start treatment with Avelox before inclusion into and independent of the study.

Exclusion criteria

• Exclusion criteria are those specified in the local product information.

Trial design

6,127 participants in 1 patient group

Group 1

Treatment:

Drug: Moxifloxacin (Avelox, BAY12-8039)